clinical development comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
In 1945 the Dutch royal family sent 100,000 tulip bulbs to Ottawa in gratitude for Canadians having sheltered the future Queen Juliana and her family for the preceding three years during the Nazi occupation of the Netherlands. In 1946 Juliana sent another 20,500 bulbs requesting that a display be created for the hospital, and promised to send 10,000 more bulbs each year. By 1963 the Canadian Tulip Festival featured more than 2 million tulips, rising to nearly 3 million by 1995. The Netherlands continues to send 20,000 bulbs to Canada each year (10,000 from the royal family and 10,000 from the Dutch Bulb Growers Association).
Oxytocin is a peptide hormone and neuropeptide normally produced in the hypothalamus and released by the posterior pituitary. Present in animals since early stages of evolution, in humans it plays roles in behavior that include social bonding, love, reproduction, childbirth, and the period after childbirth. Oxytocin is released into the bloodstream as a hormone in response to sexual activity and during childbirth. It is also available in pharmaceutical form. In either form, oxytocin stimulates uterine contractions to speed up the process of childbirth. In its natural form, it also plays a role in maternal bonding and milk production. Production and secretion of oxytocin is controlled by a positive feedback mechanism, where its initial release stimulates production and release of further oxytocin. For example, when oxytocin is released during a uterine contraction at the start of childbirth, this stimulates the production and release of more oxytocin and an increase in the intensity and frequency of contractions. This process intensifies in frequency and continues until the triggering activity ceases. A similar process takes place during lactation and during sexual activity. Oxytocin is derived by enzymatic splitting from the peptide precursor encoded by the human OXT gene. The deduced structure of the active nonapeptide is:
=== Insulin delivery === Aquasomes with calcium phosphate ceramic cores may be useful for the pharmaceutical administration of substrates such as insulin where drug action is conformationally specific. In a 2000 study by Cherian et al., disaccharides such as trehalose were used to coat the core before insulin was loaded onto the coated cores via adsorption. Albino rats were used as test subjects to test these aquasome insulin formulations, and the efficiency of different carbohydrate coat molecules on the aquasome was explored. Pyridoxal-5-phosphate-coated particles were shown to lower blood glucose levels more efficiently when compared to trehalose- or cellobiose-coated particles, which may be due to their differences in structural stability. The use of these nanoparticles for the delivery of insulin in vivo in rabbits demonstrated that insulin-bearing aquasomes showed slower release and prolonged activity compared to standard insulin solution. Similar to their role in carrying hemoglobin, the carbohydrate layer of aquasomes may be responsible for the ability to protect insulin from degradation when injected subcutaneously as in the albino rats tested. Aquasomes were also shown to release insulin in controlled manners, mimicking the typical release of insulin from the pancreas.
Sources: en.wikipedia.org
== Lithium metatitanate == Lithium metatitanate is a compound with the chemical formula Li2TiO3. It is a white powder with a melting point of 1,533 °C (2,791 °F). It is also used as an additive in porcelain enamels and ceramic insulating bodies based on titanates. It is frequently utilized as a flux due to its good stability. In recent years, along with other lithium ceramics, metatitanate pebbles have been the subject of research efforts towards tritium breeding materials in nuclear fusion applications.
== Challenges and limits == Measuring beta-cell function requires the rate of secretion to be interpreted in relation to the prevailing glucose concentration. Therefore, a mathematical model is needed that links the time courses of insulin secretion and glucose concentration as a mechanistic causal relationship.
== Critiques == Critics say that TCM theory and practice have no basis in modern science, and that TCM practitioners do not agree on what diagnosis and treatments should be used for any given person. A 2007 editorial in the journal Nature wrote that TCM "remains poorly researched and supported, and most of its treatments have no logical mechanism of action." It also described TCM as "fraught with pseudoscience". A review of the literature in 2008 found that scientists are "still unable to find a shred of evidence" according to standards of science-based medicine for traditional Chinese concepts such as qi, meridians, and acupuncture points, and that the traditional principles of acupuncture are deeply flawed. "Acupuncture points and meridians are not a reality", the review continued, but "merely the product of an ancient Chinese philosophy". In June 2019, the World Health Organization included traditional Chinese medicine in a global diagnostic compendium, but a spokesman said this was "not an endorsement of the scientific validity of any Traditional Medicine practice or the efficacy of any Traditional Medicine intervention." A 2012 review of cost-effectiveness research for TCM found that studies had low levels of evidence, with no beneficial outcomes. Pharmaceutical research on the potential for creating new drugs from traditional remedies has had few successful results. Proponents suggest that research has so far missed key features of the art of TCM, such as unknown interactions between various ingredients and complex interactive biological systems.
Sources: en.wikipedia.org
==== 2017: First full season ==== Following an off-season workout in January 2017, McCormick was hospitalized at PeaceHealth Sacred Heart Medical Center at RiverBend along with two other Oregon athletes; he remained in the hospital for several days. McCormick, along with two other athletes, exhibited high levels of creatine kinase, indicating possible rhabdomyolysis following their strenuous workout. In response to the hospitalizations, Oregon suspended their strength-and-conditioning coach without pay, among other measures. The two other student-athletes who were hospitalized during this episode later sued Oregon, alleging negligence, in 2019; McCormick did not, saying that he wished to put the situation behind him. During the 2017 Oregon Ducks football season, McCormick started two games, though his statistics were limited to six catches for eighty-nine yards and one touchdown during a total of thirteen games played.
I think that's nice because I've been lost, and I think a lot of people are lost." Ari's brother Tane Parata (Ethan Browne), their nephew Nikau Parata (Kawakawa Fox-Reo), and sister-in-law Gemma Parata (Bree Peters) were introduced in early 2020. The Paratas were the serial's first Māori family and first indigenous family to join the main cast. The actors are all New Zealand born with a Māori background. Browne revealed that the actors all auditioned together, with Kipa-Williams, Peters and Fox-Reo starting the following week, while he started a couple of months after. They established a close bond, with Kipa-Williams explaining "What's special for me is whānau, which is the Maori word for family. The cool thing about being on the show is that all of us, we didn't know each other – and I think our cultural bond bonded us to help bring what you see on screen. That gave us a sense of togetherness that came quite easily for us." Kipa-Williams said the viewers would hear different accents, humour and cultural behaviour from the family, which he thought was "nice", as every new family brings "a new vibe" to the show, but the Paratas would also bring a new culture too. Kipa-Williams, Browne and Fox-Reo wanted to include as much of the Māori culture in the show as possible, but they were unsure how much they could include. Kipa-Williams said that they started off introducing various Māori words in their dialogue, before working with the producers and scriptwriters to achieve more authenticity.
Felines, especially domestic cats, are well known for having penile spines. Upon withdrawal of a cat's penis, the spines rake the walls of the female's vagina, which may serve as a trigger for ovulation. Many other felid species have penile spines, but they are relatively small in jaguars and pumas, and do not occur in margays. Penile spines in chimpanzees and mice are small surface projections made by the piling up of keratinized cell layers in the outermost skin surface. They occur in wombats, koalas, spotted hyenas, fossas, echidnas, primates, bats, and several rodent species. Penile spines are often found in primate species that form copulatory plugs after mating. In galagos, penile spines may form a "genital lock" during copulation.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.